Good

THE HOME DEPOT UNVEILS SEASONAL SAVINGS DURING SPRING BLACK FRIDAY EVENT

Retrieved on: 
Tuesday, April 2, 2024
Lithium, Garden, Friends, Full Bloom, The Home Depot, Relaxation, Gardening, Trust, Tool, RYOBI, Flower, Makita, Plant, DeWalt, Good, Supercalifragilisticexpialidocious, Family

ATLANTA, April 2, 2024 /PRNewswire/ -- The Home Depot is kicking off its Spring Black Friday , setting up customers to go from doing to done with month-long seasonal savings on products to make their homes warm-weather ready.

Key Points: 
  • ATLANTA, April 2, 2024 /PRNewswire/ -- The Home Depot is kicking off its Spring Black Friday , setting up customers to go from doing to done with month-long seasonal savings on products to make their homes warm-weather ready.
  • This event is our way of helping doers make the most of the spring season," said Billy Bastek, executive vice president of merchandising for The Home Depot.
  • With new savings being unveiled throughout April, The Home Depot's Spring Black Friday is the perfect time to stock up on seasonal must-haves for both indoor and outdoor do-it-yourself needs at an exceptional value.
  • For everything needed for spring, customers can visit their local Home Depot stores or browse online at www.homedepot.com/springblackfriday April 4 – 28, 2024, while supplies last.

Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2023

Retrieved on: 
Sunday, March 31, 2024
Shekel, Season, Tax, Agreement, Dorad Power Station, SWAP, Sale, P-50, Depreciation, Disclosure, Bank statement, RDL, Electricity, Klahim, Legislation, AMPA, Iron, Public expenditure, Good, Israeli new shekel, PPA, Zorlu, Komemiyut, Bank Mizrahi-Tefahot, Acquisition, PV, EBIDTA, Loss, D&O, Greenhouse, Government, Total, Renewable energy

•  Operating expenses were approximately €22.9 million for the year ended December 31, 2023, compared to approximately €23.7 million for the year ended December 31, 2022.

Key Points: 
  • •  Operating expenses were approximately €22.9 million for the year ended December 31, 2023, compared to approximately €23.7 million for the year ended December 31, 2022.
  • •  Project development costs were approximately €4.5 million for the year ended December 31, 2023, compared to approximately €3.8 million for the year ended December 31, 2022.
  • During 2023, the Ellomay Solar project (28 MW) produced revenues from the sale of electricity and green certificates of approximately €4 million.
  • The Company's EBITDA may not be indicative of the Company's historic operating results; nor is it meant to be predictive of potential future results.

InstantGMP™ Welcomes Pharmsmart as a Valued Client in Expanding International Operations

Retrieved on: 
Wednesday, March 27, 2024
APVMA, Good manufacturing practice, Partnership, Animal Health, Pesticide, GMP, Good, FDA, Document management system, Medical device

CARY, N.C., March 27, 2024 /PRNewswire-PRWeb/ -- InstantGMP™, a leading provider of manufacturing software solutions ensuring Good Manufacturing Practices (GMP) and FDA compliance, proudly announces its partnership with Pharmsmart, an Australian company specializing in the development and manufacturing of Animal Health products.

Key Points: 
  • The addition of Pharmsmart to InstantGMP's clientele marks a strategic step in the company's ongoing expansion in the Asia Pacific region.
  • As InstantGMP continues to solidify its presence globally, the collaboration with Pharmsmart exemplifies a shared commitment to excellence and adherence to international quality standards.
  • Pharmsmart's decision to opt for InstantGMP™ INV software can be attributed to its comprehensive features, particularly the Equipment Management Module .
  • This ensures that Pharmsmart operators can access the system at any time and from anywhere, providing unprecedented flexibility in managing equipment and maintaining compliance.

MediPharm Labs Reports Fourth Quarter and Full Year Results

Retrieved on: 
Wednesday, March 27, 2024
OPEX, Brazilian Health Regulatory Agency, CFO, International, Webcast, Patient, VIVO, Research, Good manufacturing practice, Acquisition, Prescription, ANVISA, GMP, Adjustment, TSX, Cannabis, Good, THC, Marketing, Fine chemical

TORONTO, March 27, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.

Key Points: 
  • TORONTO, March 27, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
  • MediPharm has two medical cannabis products with ANVISA authorizations and will increase deliveries to a new pharma partner in 2024.
  • David Pidduck, CEO, MediPharm Labs commented, "MediPharm now has the margins, Opex and Adjusted EBITDA results all trending in the right direction.
  • We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

Tim Hortons and Too Good To Go continue partnership to reduce food waste with 2,000 Tims restaurants now participating and more to come

Retrieved on: 
Wednesday, March 27, 2024
Partnership, Good, TIMS, City, Too Good, Grocery store

TORONTO, March 27, 2024 /CNW/ - More than half of Canada's Tim Hortons restaurants are now working with Too Good To Go to help reduce food waste.

Key Points: 
  • TORONTO, March 27, 2024 /CNW/ - More than half of Canada's Tim Hortons restaurants are now working with Too Good To Go to help reduce food waste.
  • The Too Good To Go app offers guests a chance to purchase surplus foods from the end of the day with a goal of preventing food waste.
  • A Too Good To Go selection from Tim Hortons could include donuts, Timbits, bagels, cookies, muffins and other baked goods.
  • More Tim Hortons restaurants in St. John's, N.L., Halifax, Charlottetown, Fredericton, Moncton and Saint John, N.B., will start working with Too Good to Go this week.

UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Retrieved on: 
Tuesday, March 26, 2024
Good, Webcast, Telephone

RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .

Key Points: 
  • RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
  • Due to scheduling conflicts and the Good Friday stock market holiday, the Company will now host its conference call to discuss the financial results as well as provide a corporate update on Monday, April 1, 2024, at 8:30 a.m.
  • A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events .
  • Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-877-704-4453 or internationally +1-201-389-0920.

Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium

Retrieved on: 
Tuesday, March 26, 2024
Well, Dicarboxylic acid, University, Culture, B cell, Ajinomoto, Growth, Cell, Drug discovery, Biomedical Research, Active ingredient, Good manufacturing practice, Research, GMP, University of Tokyo, Regenerative medicine, API, Good, Amino acid, Multimedia, IPSC, Fine chemical

TOKYO, March 26, 2024  /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).

Key Points: 
  • TOKYO, March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium.
  • The product line-up of StemFit™ is ideal for regenerative medicine, drug discovery and disease modeling.
  • Additionally, it also enhances further manufacturing of cellular medicines, ensuring superior performance and reliability in iPSC culture.
  • The Group's expertise in GMP API production contributes to the superior performance of the StemFit™ medium, ensuring it meets the highest industry standards.

Future FinTech Enters into Bitcoin Mining Hosting Agreement for its Cryptocurrency Farm in Norwalk, Ohio

Retrieved on: 
Tuesday, March 26, 2024
Bitcoin, Agreement, Bitmain, Fintech, Mining, Calendar, Good, Kilowatt-hour, Cryptocurrency

The final calculation of the total server load will be based on the actual number of bitcoin miner installations.

Key Points: 
  • The final calculation of the total server load will be based on the actual number of bitcoin miner installations.
  • Mr. Kai Xu, Chief Inspector of Future FinTech's Blockchain Division, said, "We are pleased to have entered into this agreement with Teracrypto to provide them with our hosting services and the power supply for them to engage in bitcoin mining on our cryptocurrency mining farm in the US.
  • We view the timing as fortuitous for cryptocurrency mining as Bitcoin prices have recently reached their all-time high and continue to trade at record levels."
  • We believe that our hosting services for the mining farm will be successful and that we will meet the goals that we have set out for it."

The9 Signed a Definitive Share Purchase Agreement to Invest in GenAI LLM Digital Precision Medicine Platform for Brain Disease WM Therapeutic

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Depression, Sleep, The9, Synthetic media, Annual report, Myenteric plexus, Agreement, Disease, Alzheimer's disease, Central nervous system, Attention deficit, Bipolar disorder, Anxiety, AI, IPO, Insurance, Sympathetic nervous system, LLM, Drug development, WM, Spectrum, Good, Generative, Pharmaceutical industry

SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.

Key Points: 
  • SHANGHAI, March 26, 2024 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares.
  • With the signing of this Agreement, The9 will own 30% of WM Therapeutic.
  • The9 is also granted a purchase option to purchase up to 51% of the total shares of WM Therapeutic under certain conditions.
  • WM Therapeutic develops GenAI large language model brain disease screening platform and digital human personalized psychological consultant, AI precision diagnostic equipment, personalized neuromodulation treatment equipment, Generative AI large language model and AI drug clinical research platform.

First Horizon Foundation Celebrates the Company's 160th Anniversary with $1.6 Million in Donations

Retrieved on: 
Monday, March 25, 2024
Good, Organization, First Horizon Bank, First Horizon Corporation, Growth, Pharmaceutical industry

MEMPHIS, Tenn., March 25, 2024 /PRNewswire/ -- In honor of First Horizon Corp.'s 160th anniversary, First Horizon Foundation today announced the Grants for Good campaign, providing $1.6 million to non-profit organizations within the company's footprint. First Horizon Foundation will award 160 grants of $10,000 each to nonprofit organizations dedicated to strengthening the communities it serves.

Key Points: 
  • First Horizon Foundation Launches Grants for Good,
    MEMPHIS, Tenn., March 25, 2024 /PRNewswire/ -- In honor of First Horizon Corp.'s 160th anniversary, First Horizon Foundation today announced the Grants for Good campaign, providing $1.6 million to non-profit organizations within the company's footprint.
  • First Horizon Foundation will award 160 grants of $10,000 each to nonprofit organizations dedicated to strengthening the communities it serves.
  • Grants for Good is open to any 501(c)(3) organization eligible to receive funding from First Horizon Foundation.
  • Nonprofits can apply through the First Horizon website and only one application per nonprofit organization is permitted.